November 4, 2022
The Globe and Mail | Aurinia stock sinks to three-year low as B.C. biotech cuts sales forecast for lupus drug
David Martin, Head of Bloom Burton Equity Research team discusses the latest Aurinia Pharmaceuticals (NASDAQ:AUPH) quarterly results in The Globe and Mail:
